77 patents
Utility
Iloperidone Metabolite for Use In the Treatment of Psychiatric Disorders
18 Jan 24
R-P88 is used for the treatment of disorders amenable to treatment with an atypical antipsychotic.
Deepak Phadke, Curt D. Wolfgang, Mihael H. Polymeropoulos, John Joseph Feeney, Gunther Birznieks
Filed: 26 Sep 23
Utility
Method of Treatment with Tradipitant
7 Dec 23
Disclosed herein is a method of treatment of gastric motility disorders and of improving gastric motility comprising treatment with the NK-1 receptor antagonist, tradipitant.
Mihael H. Polymeropoulos, Gunther Birznieks
Filed: 16 Aug 23
Utility
Treatment of Public Speaking Anxiety with an ALPHA-7 Nicotinic Acetylcholine Receptor Agonist
30 Nov 23
Disclosed herein is a method of treatment or prevention of public speaking anxiety (PSA), which may in some cases present as a symptom of social anxiety disorder (SAD), including the performance only (SAD-PO) subtype of SAD.
Mihael H. Polymeropoulos, Christos Polymeropoulos, Yunsheng He
Filed: 24 Nov 21
Utility
Highly Purified Pharmaceutical Grade Tasimelteon
30 Nov 23
A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
Filed: 31 Jul 23
Utility
Liquid Tasimelteon Formulations and Methods of Use Thereof
23 Nov 23
Liquid suspensions of tasimelteon and methods for their use.
Deepak Phadke, Mihael Polymeropoulos
Filed: 31 Jul 23
Utility
Methods of Treating Pde Iv-mediated Diseases or Conditions
16 Nov 23
Vuk KOPRIVICA
Filed: 10 Sep 21
Utility
Multiple Myeloma Treatment
2 Nov 23
The invention relates generally to the treatment of multiple myeloma.
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Filed: 12 Jul 23
Utility
Identification and Use of Compounds In the Treatment or Prevention of Severe Acute Respiratory Syndrome Coronavirus 2
2 Nov 23
Methods for identifying compounds useful in treating or preventing infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are described, as are methods of treating or preventing SARS-CoV-2 infection using such compounds.
Mihael H. POLYMEROPOULOS, Sandra SMIESZEK, Bartlomiej PRZYCHODZEN, Vasilios M. POLYMEROPOULOS
Filed: 26 Mar 21
Utility
Methods for the Administration of Iloperidone
19 Oct 23
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
Curt D. Wolfgang, Mihael H. Polymeropoulos
Filed: 15 May 23
Utility
Method of Treatment
21 Sep 23
One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions.
Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
Filed: 23 May 23
Utility
Cancer Treatment
17 Aug 23
The invention relates generally to the treatment of cancer.
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Filed: 25 Apr 23
Utility
Improved Treatment of Atopic Dermatitis with Tradipitant
20 Jul 23
The disclosure relates generally to improvements in the treatment of pruritus, atopic dermatitis (AD), and associated symptoms with tradipitant.
Mihael H. Polymeropoulos, Gunther Birznieks, Christos Polymeropoulos
Filed: 24 Feb 21
Utility
Treatment of Circadian Rhythm Disorders
6 Jul 23
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 14 Mar 23
Utility
Highly Purified Pharmaceutical Grade Tasimelteon
18 May 23
A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
Filed: 3 Jan 23
Utility
Treatment of Lower Respiratory Tract Infection with Tradipitant
11 May 23
Disclosed herein is a method of treatment of a lower respiratory tract infection caused by, e.g., coronavirus disease (COVID-19), influenza, or other virus, comprising treatment with the NK-1 receptor antagonist, tradipitant.
Mihael H. Polymeropoulos, Christos Polymeropoulos, Vasilios Polymeropoulos, Changfu Xiao
Filed: 24 Mar 21
Utility
Treatment of Atopic Dermatitis with Tradipitant
9 Mar 23
The disclosure relates to improved methods of treatment of atopic dermatitis and symptoms thereof with tradipitant.
Mihael H. Polymeropoulos, Changfu Xiao, Gunther Birznieks, Andrew Heitman, Sandra Smieszek
Filed: 7 Nov 22
Utility
Ophthalmic Pharmaceutical Compositions
26 Jan 23
Udaya KOTREKA, Deepak PHADKE
Filed: 4 Dec 20
Utility
Melatonin Agonist Treatment
26 Jan 23
Melatonin Agonist, MA-1, is administered at effective doses.
Gunther P. Birznieks, Deepak Phadke, Mihael H. Polymeropoulos
Filed: 14 Oct 22
Utility
Depot Administration of Iloperidone
26 Jan 23
Methods of preparing and administering an injectable depot formulation of crystalline iloperidone are disclosed herein.
Mihael H. Polymeropoulos
Filed: 27 Sep 22
Utility
Treatment of CYR61- and Vegf-mediated Conditions
22 Dec 22
The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator.
Mihael H. POLYMEROPOULOS, Louis William LICAMELE, Christian LAVEDAN
Filed: 25 Aug 22